In the phase III THE3RESA study, HER2-positive advanced breast cancer patients who had previously received trastuzumab and lapatinib were assigned to the T-DM1 group and the doctor's choice treatment group (47% crossed to the T-DM1 group). Here, ERBB2 is linked to breast carcinoma.